These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 20808288)

  • 1. Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses.
    Rojas JJ; Guedan S; Searle PF; Martinez-Quintanilla J; Gil-Hoyos R; Alcayaga-Miranda F; Cascallo M; Alemany R
    Mol Ther; 2010 Nov; 18(11):1960-71. PubMed ID: 20808288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway.
    Cascallo M; Alonso MM; Rojas JJ; Perez-Gimenez A; Fueyo J; Alemany R
    Mol Ther; 2007 Sep; 15(9):1607-15. PubMed ID: 17579575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.
    Wang F; Wang Z; Tian H; Qi M; Zhai Z; Li S; Li R; Zhang H; Wang W; Fu S; Lu J; Rodriguez R; Guo Y; Zhou L
    Curr Gene Ther; 2012 Apr; 12(2):67-76. PubMed ID: 22384806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo.
    Alonso MM; Cascallo M; Gomez-Manzano C; Jiang H; Bekele BN; Perez-Gimenez A; Lang FF; Piao Y; Alemany R; Fueyo J
    Cancer Res; 2007 Sep; 67(17):8255-63. PubMed ID: 17804740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
    Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
    Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
    Zhu M; Bristol JA; Xie Y; Mina M; Ji H; Forry-Schaudies S; Ennist DL
    J Virol; 2005 May; 79(9):5455-65. PubMed ID: 15827160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses.
    Rojas JJ; Cascallo M; Guedan S; Gros A; Martinez-Quintanilla J; Hemminki A; Alemany R
    Gene Ther; 2009 Dec; 16(12):1441-51. PubMed ID: 19710704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.
    Wong HH; Jiang G; Gangeswaran R; Wang P; Wang J; Yuan M; Wang H; Bhakta V; Müller H; Lemoine NR; Wang Y
    Mol Ther; 2012 Feb; 20(2):306-16. PubMed ID: 22086234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
    Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY
    Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors.
    Zhang J; Wei F; Wang H; Li H; Qiu W; Ren P; Chen X; Huang Q
    Cancer Biother Radiopharm; 2010 Aug; 25(4):487-95. PubMed ID: 20735209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication.
    Hernandez-Alcoceba R; Pihalja M; Qian D; Clarke MF
    Hum Gene Ther; 2002 Sep; 13(14):1737-50. PubMed ID: 12396626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
    Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
    Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus.
    Shashkova EV; Spencer JF; Wold WS; Doronin K
    Mol Ther; 2007 Mar; 15(3):598-607. PubMed ID: 17191072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells.
    Wei F; Wang H; Chen X; Li C; Huang Q
    Cancer Biol Ther; 2014 Oct; 15(10):1358-66. PubMed ID: 25019940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Delta24RGD.
    Majem M; Cascallo M; Bayo-Puxan N; Mesia R; Germa JR; Alemany R
    Cancer Gene Ther; 2006 Jul; 13(7):696-705. PubMed ID: 16498429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma double-regulated oncolytic adenovirus.
    Zhang KJ; Wang YG; Cao X; Zhong SY; Wei RC; Wu YM; Yue XT; Li GC; Liu XY
    Hum Gene Ther; 2009 Aug; 20(8):818-30. PubMed ID: 19320563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.